EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stake Increased by Point72 Asset Management L.P.

Point72 Asset Management L.P. increased its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 90.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 857,853 shares of the company's stock after buying an additional 406,535 shares during the period. Point72 Asset Management L.P. owned about 1.26% of EyePoint Pharmaceuticals worth $6,391,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in EYPT. RA Capital Management L.P. acquired a new position in EyePoint Pharmaceuticals during the 4th quarter worth approximately $23,705,000. TCG Crossover Management LLC boosted its holdings in shares of EyePoint Pharmaceuticals by 287.3% in the 4th quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock valued at $26,614,000 after buying an additional 2,650,000 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of EyePoint Pharmaceuticals by 51.7% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after buying an additional 1,958,580 shares in the last quarter. Federated Hermes Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 92.7% in the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock valued at $27,620,000 after buying an additional 1,783,765 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock valued at $28,334,000 after buying an additional 755,045 shares in the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Trading Up 1.4%

Shares of EYPT traded up $0.08 during trading hours on Friday, reaching $5.68. The company had a trading volume of 368,862 shares, compared to its average volume of 815,934. The firm has a 50 day simple moving average of $5.82 and a 200-day simple moving average of $7.09. The company has a market capitalization of $390.85 million, a price-to-earnings ratio of -2.84 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a 12-month low of $3.91 and a 12-month high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million. Sell-side analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Analysts Set New Price Targets

EYPT has been the subject of several research analyst reports. Wall Street Zen upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Chardan Capital lowered their target price on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, Mizuho decreased their price target on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday, May 16th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $25.38.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.